Regional dialogues between the Government and the business community on Ukraine’s EU accession are continuing across the country. The meeting held on 4 June 2026 in Zakarpattia, was dedicated to the opportunities and challenges facing the pharmaceutical sector in this process. Senior representatives of pharmaceutical manufacturers and distributors had the opportunity to engage directly with Ukrainian government officials, representatives of EU institutions, and industry experts.
Integration into European Union markets opens new opportunities for Ukrainian businesses. At the same time, companies that are adapting to EU standards while operating under the pressures of war require government support, regulatory clarity, and confidence that their competitiveness can be maintained. It is for this reason that the Office of the Deputy Prime Minister for European and Euro-Atlantic Integration of Ukraine, with the support of the Ukraine2EU programme, is organising a series of practical dialogues with representatives of key sectors of the Ukrainian economy.
Discussions in Zakarpattia focused on regulatory procedures, legislative alignment timelines and institutional capacity; the modernisation of pharmaceutical manufacturing; the Critical Medicines Act; and Ukraine’s integration into European pharmaceutical supply chains.
Ukraine is actively implementing regulatory standards harmonised with EU requirements, including Good Manufacturing Practice (GMP). The European Commission noted the substantial progress made by Ukraine as an EU accession candidate during the bilateral screening under Chapter 28 ‘Consumer Protection and Public Health’. Ukraine’s principal tasks at this stage are the full alignment of its regulatory framework with EU requirements and the transition to a modern, effective system of state control.
Ukraine’s pharmaceutical sector comprises more than 50 large and medium-sized manufacturing facilities and over 15,000 registered medicinal products. Despite the war, the pharmaceutical sector has preserved its production capacity, innovation potential, and domestic demand. Companies have demonstrated a high degree of resilience and adaptability, rapidly restoring supply chains to ensure uninterrupted access to medicines. Six Ukrainian manufacturers have joined the EU Alliance on Critical Medicines — an initiative designed to address shortages of essential medicines across Europe.
In the context of the EU’s active efforts to diversify pharmaceutical supply chains, Ukraine can become a reliable partner in strengthening the resilience of these chains. In addition, Ukraine’s investment attractiveness can also be considered in the context of the opportunities opened up for investors by the post-war reconstruction and modernisation of the healthcare system.
Regional dialogues with business held at the regional level help translate the EU accession process into clear decisions and opportunities for Ukrainian companies. The initiative provides a structured platform for businesses to share their views, raise practical questions, and gain a better understanding of how European integration affects their operations, strategic planning, and future development.
* More information at the link https://eu-ua.kmu.gov.ua/en/news/ukrainian-pharmaceutical-sector-adapts-to-eu-standards-despite-the-war-as-government-and-business-continue-dialogue-on-eu-accession/